Table 4.
Weighted mean effect sizes for prospective longitudinal studies.
| Study: Authors, reference, timing of follow-up | k | Fixed effect model |
Random effect model |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Effect size (SE) | 95% CI | z | Q | Effect size (SE) | 95% CI | z | Q | ||
| Grand mean weighted effect size | 228 | 0.11 (0.01)* | 0.09 to 0.14 | 8.78 | 1212.07* | 0.16 (0.03)* | 0.09 to 0.22 | 5.03 | 615.63* |
| Bender et al. (38), 1 week follow-up | 18 | 1.02 (0.10)* | 0.82 to 1.22 | 10.01 | 141.21* | 1.12 (0.14)* | 0.83 to 1.40 | 7.73 | 77.50* |
| Bender et al. (38),1 year follow-up | 16 | 0.55 (0.13)* | 0.30 to 0.79 | 4.36 | 266.88* | 0.70 (0.16)* | 0.38 to 1.03 | 4.30 | 181.48* |
| Collins et al. (33),1 year follow-up | 23 | 0.21 (0.04)* | 0.13 to 0.29 | 5.08 | 13.69* | 0.21 (0.09)* | 0.03 to 0.39 | 2.24 | 2.64 |
| Collins et al. (33),1 month follow-up | 23 | 0.10 (0.04)* | 0.02 to 0.18 | 2.36 | 12.07 | 0.10 (0.09) | −0.09 to 0.28 | 1.03 | 2.31 |
| Collins et al. (34), During chemotherapy | 13 | −0.22 (0.06)* | −0.34 to −0.10 | − 3.58 | 191.60* | −0.26 (0.13)* | −0.51 to −0.00 | − 1.98 | 182.66* |
| Debess et al. (37), 4 weeks follow-up | 5 | 0.20 (0.07)* | 0.06 to 0.34 | 2.75 | 2.94 | 0.20 (0.19) | −0.18 to 0.58 | 1.03 | 0.42 |
| Hermelink et al. (25), between last second and last chemotherapy | 12 | 0.20 (0.04)* | 0.12 to 0.28 | 5.05 | 19.90 | 0.20 (0.12) | −0.04 to 0.45 | 1.67 | 2.15 |
| Hurria et al. (16),6 months follow-up | 13 | 0.05 (0.08) | −0.10 to.0.20 | 0.68 | 8.71 | 0.05 (0.14) | −0.21 to 0.32 | 0.40 | 2.79 |
| Jansen et al. (35),6 months follow-up | 7 | −0.08 (0.07) | −0.22 to 0.05 | −1.19 | 254.66* | −0.29 (0.17) | −0.62 to 0.04 | −1.71 | 64.30* |
| Jenkins et al. (43),18 months follow-up | 14 | 0.08 (0.04) | −0.00 to 0.16 | 1.95 | 19.79 | 0.08 (0.11) | −0.14 to 0.31 | 0.70 | 2.54 |
| Jenkins et al. (43),4 weeks follow-up | 14 | 0.03 (0.04) | −0.05 to 0.11 | 0.80 | 11.65 | 0.03 (0.11) | −0.19 to 0.26 | 0.29 | 1.49 |
| Shilling et al. (19),6 months follow-up | 9 | 0.05 (0.07) | −0.08 to 0.18 | 0.73 | 15.89 | 0.05 (0.15) | −0.24 to 0.34 | 0.33 | 3.19 |
| Stewart et al. (18),2 months follow-up | 23 | 0.12 (0.04)* | 0.04 to 0.19 | 3.03 | 13.50 | 0.12 (0.09) | −0.06 to 0.30 | 1.28 | 2.37 |
| Vearncombe et al. (17), 4 weeks follow-up | 14 | 0.06 (0.03)* | 0.00 to 0.13 | 1.98 | 66.04* | 0.06 (0.11) | −0.16 to 0.28 | 0.57 | 5.67 |
| Wefel et al. (27), 3 weeks follow-up | 10 | 0.18 (0.11) | −0.03 to 0.38 | 1.67 | 2.47 | 0.18 (0.17) | −0.15 to 0.50 | 1.07 | 1.01 |
| Wefel et al. (27), 1 year follow-up | 10 | 0.26 (0.11)* | 0.04 to 0.48 | 2.33 | 3.20 | 0.26 (0.17) | −0.07 to 0.59 | 1.55 | 1.41 |
| Wefel et al. (27), 1 year follow-up | 6 | 0.22 (0.10)* | 0.02 to 0.42 | 2.16 | 15.66* | 0.22 (0.19) | −0.16 to 0.60 | 1.14 | 4.33 |
| Q total (df = 228) | 1212.07* | Q total (df = 228) | 615.63* | ||||||
| Q within (df = 211) | 1059.84* | Q within (df = 211) | 538.24* | ||||||
| Q between (df = 16) | 152.22* | Q between (df = 16) | 77.39* | ||||||
*p < 0.05.